Your browser doesn't support javascript.
loading
Development of Shortened miR-506-3p Mimics Exhibiting Strong Differentiation-Inducing Activity in Neuroblastoma Cells.
Mesa-Diaz, Nakya; Smith, Mitchell T; Cardus, Daniela F; Du, Liqin.
Afiliação
  • Mesa-Diaz N; Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX 78666, USA.
  • Smith MT; Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX 78666, USA.
  • Cardus DF; Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX 78666, USA.
  • Du L; Department of Chemistry and Biochemistry, Texas State University, San Marcos, TX 78666, USA.
Molecules ; 28(17)2023 Aug 28.
Article em En | MEDLINE | ID: mdl-37687123
ABSTRACT
microRNA mimics are synthetic RNA molecules that imitate the mature miRNA duplexes and their functions. These mimics have shown promise in treating cancers. Nucleotide chemical modifications of microRNA mimics have been investigated and have improved the stability of miRNA mimics. However, the potential therapeutic benefit of mimic analogs based on sequence modifications has not been explored. miR-506-3p was identified as a differentiation-inducing microRNA in neuroblastoma cells, suggesting the potential of applying the miR-506-3p mimic in neuroblastoma differentiation therapy. In this study, we explored the possibility of developing shortened miR-506-3p analogs that can maintain differentiation-inducing activities comparable to the wild-type miR-506-3p mimic. We found that deleting up to two nucleotides at either the 3' end or within the middle region of the miR-506-3p sequence fully maintained the differentiation-inducing activity when compared to the wild-type mimic. Deleting up to four nucleotides from the 3' end or deleting three nucleotides in the middle positions diminished the differentiation-inducing activity, but the analogs still maintained differentiation-inducing activities that were significantly higher than the negative control oligo. The shortened analog designs potentially benefit patients from two perspectives (1) the reduced cost of manufacturing shortened analogs, and (2) the reduced non-specific toxicity due to their smaller molecular sizes.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: MicroRNAs / Células-Tronco Neurais / Neuroblastoma Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: MicroRNAs / Células-Tronco Neurais / Neuroblastoma Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article